vs
Apellis Pharmaceuticals, Inc.（APLS）与GERMAN AMERICAN BANCORP, INC.（GABC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是GERMAN AMERICAN BANCORP, INC.的1.6倍（$199.9M vs $126.7M），GERMAN AMERICAN BANCORP, INC.净利率更高（28.2% vs -29.5%，领先57.7%），GERMAN AMERICAN BANCORP, INC.同比增速更快（39.7% vs -5.9%），GERMAN AMERICAN BANCORP, INC.自由现金流更多（$154.0M vs $-14.3M），过去两年GERMAN AMERICAN BANCORP, INC.的营收复合增速更高（22.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
German American Bancorp, Inc.（股票代码：GABC）是一家美国的银行控股企业，专注于提供多元金融服务，核心业务涵盖支付卡相关服务，总部位于纽约曼哈顿下城的巴特利公园城，在金融服务领域拥有成熟的业务布局。
APLS vs GABC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $126.7M |
| 净利润 | $-59.0M | $35.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 34.6% |
| 净利率 | -29.5% | 28.2% |
| 营收同比 | -5.9% | 39.7% |
| 净利润同比 | -62.2% | 53.7% |
| 每股收益（稀释后） | $-0.40 | $0.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $126.7M | ||
| Q3 25 | $458.6M | $126.5M | ||
| Q2 25 | $178.5M | $123.2M | ||
| Q1 25 | $166.8M | $111.1M | ||
| Q4 24 | $212.5M | $90.7M | ||
| Q3 24 | $196.8M | $88.5M | ||
| Q2 24 | $199.7M | $90.5M | ||
| Q1 24 | $172.3M | $84.1M |
| Q4 25 | $-59.0M | $35.7M | ||
| Q3 25 | $215.7M | $35.1M | ||
| Q2 25 | $-42.2M | $31.4M | ||
| Q1 25 | $-92.2M | $10.5M | ||
| Q4 24 | $-36.4M | $23.2M | ||
| Q3 24 | $-57.4M | $21.0M | ||
| Q2 24 | $-37.7M | $20.5M | ||
| Q1 24 | $-66.4M | $19.0M |
| Q4 25 | -25.6% | 34.6% | ||
| Q3 25 | 48.7% | 34.6% | ||
| Q2 25 | -18.6% | 31.8% | ||
| Q1 25 | -50.0% | 12.0% | ||
| Q4 24 | -12.3% | 31.6% | ||
| Q3 24 | -24.0% | 29.0% | ||
| Q2 24 | -14.7% | 29.4% | ||
| Q1 24 | -36.0% | 27.6% |
| Q4 25 | -29.5% | 28.2% | ||
| Q3 25 | 47.0% | 27.7% | ||
| Q2 25 | -23.6% | 25.5% | ||
| Q1 25 | -55.3% | 9.5% | ||
| Q4 24 | -17.1% | 25.6% | ||
| Q3 24 | -29.2% | 23.8% | ||
| Q2 24 | -18.9% | 22.7% | ||
| Q1 24 | -38.5% | 22.6% |
| Q4 25 | $-0.40 | $0.98 | ||
| Q3 25 | $1.67 | $0.94 | ||
| Q2 25 | $-0.33 | $0.84 | ||
| Q1 25 | $-0.74 | $0.30 | ||
| Q4 24 | $-0.30 | $0.79 | ||
| Q3 24 | $-0.46 | $0.71 | ||
| Q2 24 | $-0.30 | $0.69 | ||
| Q1 24 | $-0.54 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $100.0M |
| 股东权益账面价值 | $370.1M | $1.2B |
| 总资产 | $1.1B | $8.4B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
| Q4 25 | — | $100.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $114.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.0B | ||
| Q4 24 | $228.5M | $715.1M | ||
| Q3 24 | $237.1M | $744.6M | ||
| Q2 24 | $264.3M | $687.8M | ||
| Q1 24 | $266.7M | $655.3M |
| Q4 25 | $1.1B | $8.4B | ||
| Q3 25 | $1.1B | $8.4B | ||
| Q2 25 | $821.4M | $8.3B | ||
| Q1 25 | $807.3M | $8.4B | ||
| Q4 24 | $885.1M | $6.3B | ||
| Q3 24 | $901.9M | $6.3B | ||
| Q2 24 | $904.5M | $6.2B | ||
| Q1 24 | $831.9M | $6.1B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $159.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $154.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 121.6% |
| 资本支出强度资本支出/营收 | 0.1% | 4.2% |
| 现金转化率经营现金流/净利润 | — | 4.46× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $267.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $159.3M | ||
| Q3 25 | $108.5M | $51.8M | ||
| Q2 25 | $4.4M | $26.9M | ||
| Q1 25 | $-53.4M | $37.9M | ||
| Q4 24 | $19.4M | $95.8M | ||
| Q3 24 | $34.1M | $24.5M | ||
| Q2 24 | $-8.3M | $18.7M | ||
| Q1 24 | $-133.0M | $23.9M |
| Q4 25 | $-14.3M | $154.0M | ||
| Q3 25 | $108.3M | $50.1M | ||
| Q2 25 | $4.4M | $26.2M | ||
| Q1 25 | $-53.4M | $36.7M | ||
| Q4 24 | $19.3M | $90.7M | ||
| Q3 24 | — | $23.0M | ||
| Q2 24 | $-8.4M | $17.0M | ||
| Q1 24 | $-133.3M | $22.6M |
| Q4 25 | -7.1% | 121.6% | ||
| Q3 25 | 23.6% | 39.6% | ||
| Q2 25 | 2.5% | 21.2% | ||
| Q1 25 | -32.0% | 33.0% | ||
| Q4 24 | 9.1% | 100.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | -4.2% | 18.8% | ||
| Q1 24 | -77.3% | 26.9% |
| Q4 25 | 0.1% | 4.2% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 1.1% | ||
| Q4 24 | 0.0% | 5.6% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 1.8% | ||
| Q1 24 | 0.2% | 1.5% |
| Q4 25 | — | 4.46× | ||
| Q3 25 | 0.50× | 1.48× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 3.61× | ||
| Q4 24 | — | 4.13× | ||
| Q3 24 | — | 1.16× | ||
| Q2 24 | — | 0.91× | ||
| Q1 24 | — | 1.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GABC
暂无分部数据
